Terms: = Breast cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Diagnosis
39 results:
1. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/cap updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M; Porta FM; D'Ercole M; Pescia C; Sajjadi E; Cursano G; De Camilli E; Pala O; Mazzarol G; Venetis K; Guerini-Rocco E; Curigliano G; Viale G; Fusco N
Virchows Arch; 2024 Jan; 484(1):3-14. PubMed ID: 37770765
[TBL] [Abstract] [Full Text] [Related]
2. HER2 Equivocal (Score = 2+) breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
Mohanlal RD; Bouwer N; Willem P
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):555-560. PubMed ID: 37471623
[TBL] [Abstract] [Full Text] [Related]
3. [Susceptibility study on the germline rare variants of bromodomain and extraterminal domain protein family-encoding genes and patients with cancer living in some regions of China].
Huang Y; Li JH; Wang X; Zou Y; Huang WF; Liu C; Zhang H
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(42):3374-3381. PubMed ID: 36372767
[No Abstract] [Full Text] [Related]
4. Extranodal extension, an international survey on its evaluation and reporting in breast cancer patients.
Tang P; Moravek M; Oprea-Ilies G; Mon KS; Pambuccian SE
Pathol Res Pract; 2022 Sep; 237():154070. PubMed ID: 36030639
[TBL] [Abstract] [Full Text] [Related]
5. Hsa_circRNA_0040462: a sensor of cells' response to cap treatment with double-edged roles on breast cancer malignancy.
Tian Y; Zhang Z; Zhang Z; Dai X
Int J Med Sci; 2022; 19(4):640-650. PubMed ID: 35582416
[TBL] [Abstract] [Full Text] [Related]
6. Effect of the 2013 ASCO-cap HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive breast cancer.
Yamada M; Kubo M; Yamamoto H; Yamashita N; Kai M; Zaguirre K; Kaneshiro K; Shimazaki A; Hayashi S; Kawaji H; Mori M; Oda Y; Nakamura M
Anticancer Res; 2021 Aug; 41(8):4143-4149. PubMed ID: 34281885
[TBL] [Abstract] [Full Text] [Related]
7. An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/cap Guideline.
Wang C; Tsang JY; Poon IK; Shao Y; Li JJ; Shea KH; Hlaing T; Wong SI; Tse GM
Clin Breast Cancer; 2022 Jan; 22(1):e114-e122. PubMed ID: 34119429
[TBL] [Abstract] [Full Text] [Related]
8. Emerging roles of circular RNAs in thyroid cancer.
Chen L; Sun Z; Xu H; Xie Q; Qi M; Tian X; Wang T
Exp Cell Res; 2021 Jul; 404(2):112626. PubMed ID: 34023393
[TBL] [Abstract] [Full Text] [Related]
9. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract] [Full Text] [Related]
10. [Pathological diagnosis, work-up and reporting of breast cancer. Recommendations from the 4th breast cancer Consensus Conference].
Cserni G; Francz M; Járay B; Kálmán E; Kovács I; Krenács T; Tóth E; Udvarhelyi N; Vass L; Vörös A; Kulka J
Magy Onkol; 2020 Dec; 64(4):301-328. PubMed ID: 33313608
[TBL] [Abstract] [Full Text] [Related]
11. Heritability of Low ER Staining/HER2-breast Tumors: Are We Missing an Opportunity for Germline Testing?
Lovejoy LA; Turner CE; Wells JM; Shriver CD; Ellsworth RE
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33302456
[TBL] [Abstract] [Full Text] [Related]
12. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III breast cancer: A Multicenter Value Analysis.
Hyland CJ; Varghese F; Yau C; Beckwith H; Khoury K; Varnado W; Hirst GL; Flavell RR; Chien AJ; Yee D; Isaacs CJ; Forero-Torres A; Esserman LJ; Melisko ME
J Natl Compr Canc Netw; 2020 Nov; 18(11):1510-1517. PubMed ID: 33152704
[TBL] [Abstract] [Full Text] [Related]
13. miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review.
Guo CM; Liu SQ; Sun MZ
Neoplasma; 2020 Mar; 67(2):215-228. PubMed ID: 31884798
[TBL] [Abstract] [Full Text] [Related]
14. Impact of the 2018 ASCO/cap guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
[TBL] [Abstract] [Full Text] [Related]
15. Burden of community-acquired pneumonia, predisposing factors and health-care related costs in patients with cancer.
Schmedt N; Heuer OD; Häckl D; Sato R; Theilacker C
BMC Health Serv Res; 2019 Jan; 19(1):30. PubMed ID: 30642312
[TBL] [Abstract] [Full Text] [Related]
16. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
[TBL] [Abstract] [Full Text] [Related]
17. ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.
Chen Y; Zhang B; Bao L; Jin L; Yang M; Peng Y; Kumar A; Wang JE; Wang C; Zou X; Xing C; Wang Y; Luo W
J Clin Invest; 2018 May; 128(5):1937-1955. PubMed ID: 29629903
[TBL] [Abstract] [Full Text] [Related]
18. Effects of Hydrochloric Acid and Formic Acid Decalcification on breast Tumor Biomarkers and HER2 Fluorescence In Situ Hybridization.
Clark BZ; Yoest JM; Onisko A; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):223-230. PubMed ID: 28877070
[TBL] [Abstract] [Full Text] [Related]
19. [Anatomopathological profile of breast cancer in cape bon, Tunisia].
Sahraoui G; Khanchel F; Chelbi E
Pan Afr Med J; 2017; 26():11. PubMed ID: 28450990
[TBL] [Abstract] [Full Text] [Related]
20. The Impact of 2013 Updated ASCO/cap HER2 Guidelines on the diagnosis and Management of Invasive breast cancer: A Single-Center Study of 1739 Cases.
Zhang X; Bleiweiss I; Jaffer S; Nayak A
Clin Breast Cancer; 2017 Oct; 17(6):486-492. PubMed ID: 28433541
[TBL] [Abstract] [Full Text] [Related]
[Next]
